MRNA Story - On A Smaller ScaleIn continuation of the previous idea, I wanted to cover the shorter time frame move on $NASDAQ:MRNA.
Really, this is a more simple analysis as the base is clearly set on the weekly chart. I should note I have analyzed the consolidation on the 2-Week time period. The 2-Week time period does also give a range expansion signal, but for a more detailed look I am showing the 1-Week time period.
With the current base, and a measure of this consolidation range (from low to high), a first target of $42.76 can be obtained. If the trend continues in a really strong fashion, a second target of $68.17 would look to be hit. Sometimes when an explosive move like this happens, a retest of the mode can occur like in the example path shown below. However, just as the continuation of this trend remains to be seen, so does any retest of this move. Make bets accordingly.
Whether the trend continues, and how strong it remains, of course is yet to be determined. But this analysis allows for educated guesses to be made and positions to be taken.
Best of luck to all of us who are entering positions and looking for continuation of this trend reversal play.
Pasting the regular weekly chart (no path) here:
Enjoy,
Reagen
Moderna
Moderna - Upside PotentialSince August 2021, Moderna’s stock has been in a downtrend.
The latest decline started in May 2024 and ended in April 2025, dropping from 170 to 23 .
Since April 2025, a corrective move has begun for one of the sub-waves.
This move is nearly complete, with final targets at 36 -> 38 .
This does not mean the uptrend is over - after some time and additional corrections, we should see a move toward 57 .
The longer-term outlook remains clear and largely positive.
For now, let's focus on the targets mentioned. Further developments will be shared in new ideas.
---
Please subscribe and leave a comment.
You’ll get new information faster than anyone else.
---
October’s top stock performers: #AMD, #Amazon, #Tesla & moreIn October, FreshForex clients most frequently traded stocks like #AMD, #Amazon, #GoDaddy, #Tesla, and #Moderna — and these very assets showed the highest share of profitable trades. Capitalize on strong demand momentum and high liquidity: with earnings season and the holiday rush ahead, the “window of opportunity” is still open.
Outlook through the end of 2025:
#AMD: Shares could rise following the $6B AI compute deal with OpenAI and Oracle’s reported order of 50,000 next-gen MI450 chips.
#Amazon: Strong earnings on October 30, solid AWS growth, advertising contributions, and the fall Prime Big Deal Days may keep the stock bullish.
#GoDaddy: Stock may face pressure if SMB ARPU/inflows slow, plus FX headwinds could dampen August’s raised full-year guidance.
#Tesla: Growth potential supported by record 497K deliveries, 12.5 GWh energy deployments in Q3, and expansion of FSD v14 (Supervised).
#Moderna: Stock remains under pressure amid limited revenue visibility, delayed UK shipments, and postponed approval of its flu+COVID combo vaccine to 2026.
According to FreshForex analysts, the outlook for these stocks remains driven by AI investments and seasonal demand. But the strongest growth impulse is likely in Q1 2026, especially if the Fed eases policy and announced tech projects go live.
$MRNA I might full port..Everything is noted in the chart for visualization. We have local resistance around $27 which I don't think is an issue. This name is at 5 year lows with an incredible 67% haircut over the span of a year and change, if that. NASDAQ:MRNA just crushed its last earnings beat and it dropped. A controlled and manipulated drop in my opinion. Healthcare names may have a beautiful end of the year. This is a great name to acquire for mid to long term portfolios just in shares itself. I personally will be entering calls for dated out. I am currently in $30 calls for 10/17 expiration. I expect this name to make a full 100% recovery into the psyche level of $50 in the months to come.
5 stocks that shook the market in MayMay 2025 turned out to be a landmark month for the U.S. stock market. Several top companies posted impressive gains driven by explosive demand for AI technologies, advancements in autonomous transport, and strong corporate strategy.
Here are the five market leaders that set the tone in May:
1. Nvidia – The AI Powerhouse
Nvidia (#NVIDIA) surged 25% in May, becoming the most valuable U.S. company with a market cap of $3.45 trillion — surpassing even Microsoft. The rally was fueled by stunning data center results, with revenue hitting $39.1 billion (+427% YoY). Its new Blackwell chip series has already sparked massive interest from leading AI developers. UBS analysts raised their price target to $175, predicting further growth in high-performance computing.
2. Apple – A return to growth
Apple (#Apple) saw a solid 7% gain, rebounding from earlier struggles. The company announced $500 billion in long-term investments over the next five years to create new jobs and manufacture AI servers in the U.S. This move restored investor confidence and supported the stock’s recovery.
3. Tesla – Robotaxis drive momentum
Tesla (#Tesla) jumped 25%, boosted by the announcement of its robotaxi launch in Austin, Texas, scheduled for June 12. Combined with improving market conditions and a pause in EU tariff pressure, Tesla shares reclaimed center stage. Wedbush analysts see potential for the stock to hit $500 as the company expands its autonomous and AI-driven initiatives.
4. Moderna – Biotech breakthroughs
Moderna (#Moderna) gained 7% following positive results from new cancer drug trials. The company also revealed plans to cut operational costs by $1.7 billion by 2027, aiming to boost overall efficiency. Investors welcomed the strategic pivot beyond COVID-related products.
5. Alcoa – Aluminum and geopolitics
Alcoa (#Alcoa) rose 6.5% on reports that the U.S. may ban aluminum imports from Russia. This geopolitical development, along with steady dividends and renewed investor interest in commodities, positioned Alcoa as a top-performing metals stock for the month.
May 2025 confirmed the market’s focus on AI, autonomous transport, biotech, and raw materials. Nvidia, Tesla, Apple, Moderna, and Alcoa led the charge — and FreshForex analysts recommend riding this momentum for active trading on high-performing stocks.
MODERNA $305 | Bidding at $220 and $150 Informed Players and speculators at Sub $100 levels are booking gains
we wait for additional drwadowns and re accomodation ACCUMULATION of designated Bankers for the next run up OR cycle
Vaccine COViD was intense HiV was the sell on News..
we await next Drama and Biden Policy on Healthcare etc..
for now Watch or Chrun at key leves (eyeball the box)
A Long-term Bullish Trend ?With an upcoming Earnings report we can observe rather uncertain future behavior.
But since the trend has been bearish for a longer period of time and the price is "nearly" at the same position which was achieved for the first time in early April in 2019, we can, mostly based only on the technical analysis and Earnings report, determine quite confidently that the price is ready to rise.
Important data:
EPS Estimate: -$3.12
Revenue Estimate: $106 million to $166.7 million
Notable developments:
Cost-cutting initiative = Targeting $1.1B in reductions by 2027
By the end of 2024 $9.5 billion allocated in investments
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MRNA Shares Drop?
On Monday, MRNA led the decline among US biotech stocks following the resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks had held this position for over a decade.
During Trump’s first term, Marks oversaw the rollout of COVID-19 vaccines and established guidelines for emerging treatments such as cell and gene therapy.
However, in Trump’s second term, Robert F. Kennedy Jr. now serves as Health Secretary. According to The Wall Street Journal, Marks criticised Kennedy’s stance on vaccines in his resignation letter, calling it “misinformation and lies.”
The pharmaceutical industry was already under pressure amid speculation that Trump’s tariff plans could extend to prescription drugs, which are typically exempt from such measures. Marks' departure has further intensified uncertainty regarding regulatory decisions under the new administration.
Technical Analysis of MRNA Shares
The chart indicates that:
➝ The stock remains in a downtrend that began with a sharp drop in August last year (reinforced by the moving average).
➝ Over the past five months, it has been forming a descending channel (marked in red).
➝ The lower boundary of this channel acted as support yesterday.
The formation of higher lows and highs (marked in blue) had given bulls some hope in March 2025. However, yesterday’s bearish gap appears to have shattered that optimism.
It is possible that the lower blue trendline and the median of the red channel will act as resistance moving forward, further darkening the outlook for MRNA’s share price—especially given the ongoing negative news surrounding the stock.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine'It's gone 5 years or so... (Duh..? 5 years, really? 🥴) since everyone was talking about COVID-19 pandemic, vaccines, "world will never be the same again", and so on.
- And now?..
- It's gone. It's absolutely gone..! Since nothing last forever and no one should chase a feather, or dust in the wind.
This is why we at our 💖Super-Duper Beloved @PandorraResearch Team decided to build this idea, as a educational idea to learn, even this story is about single Moderna stock, and we have reasonable considerations about fundamental, technical and price movement perspectives.
Well.. Let's the story begin...
Over the past few years, Moderna's stock has experienced a significant decline, primarily due to several key factors.
Here's a detailed explanation of why Moderna's stock has been moving downward:
1. Declining Demand for COVID-19 Vaccine
The primary reason for Moderna's stock decline is the waning demand for COVID-19 vaccines. During the pandemic, Moderna's mRNA-based vaccine was one of the first and most widely used, leading to a surge in sales and profitability. However, as the pandemic transitioned into an endemic phase, demand for vaccines decreased substantially. This shift has resulted in declining sales for Moderna, impacting its revenue and profitability.
2. Sales Guidance and Performance
In recent years, Moderna has faced challenges in meeting sales expectations. For instance, in 2025, the company forecasted sales between $1.5 billion and $2.5 billion, which was significantly lower than analysts' expectations of around $2.9 billion. This discrepancy led to a sharp decline in stock prices as investors became increasingly pessimistic about the company's future growth prospects.
3. Cost-Cutting Measures
To mitigate the impact of declining sales, Moderna has implemented cost-cutting measures. The company plans to reduce its cash operating costs by $1 billion in 2025 and an additional $500 million in 2026. While these efforts aim to improve profitability, they also reflect the challenges Moderna faces in maintaining its financial health without strong vaccine sales.
4. Competition in New Market s
Moderna is expanding into new markets, such as the respiratory syncytial virus (RSV) vaccine space, with its product mResvia. However, this market is highly competitive, with established players like Pfizer and GSK already present. The competition and uncertainty about market share have contributed to investor skepticism about Moderna's ability to drive growth through new products.
5. Delayed Break-Even Point
Initially, Moderna aimed to break even on an operating cash cost basis by 2026. However, this goal has been pushed back to 2028, indicating a slower-than-expected transition to profitability. This delay has further eroded investor confidence in the company's ability to execute its strategic plans effectively.
6. Valuation and Market Performance
Moderna's stock has underperformed both the industry and the broader market. The stock trades below its 200-day and 50-day moving averages, reflecting a lack of momentum. Additionally, Moderna's price-to-sales ratio is lower than the industry average, which might suggest undervaluation but also indicates a lack of investor enthusiasm for the stock.
7. Analyst Sentiment and Profitability Forecasts
Analysts have become increasingly pessimistic about Moderna's prospects, with many not expecting the company to turn profitable again until at least 2029. This negative outlook has contributed to the downward pressure on the stock. Furthermore, estimates for loss per share have increased, reinforcing the bearish sentiment among investors.
In summary, Moderna's stock decline is primarily driven by declining vaccine demand, missed sales expectations, increased competition in new markets, delayed profitability, and negative analyst sentiment. While the company is taking steps to adapt to these challenges, the path to recovery remains uncertain, contributing to ongoing investor skepticism.
--
Best 'No more Covid' wishes,
@PandorraResearch Team 😎
Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment among investors.
Weighing the Challenges and Opportunities
On Friday, Moderna disclosed a Q4 2024 revenue of $966 million, marking a sharp 65% year-over-year decline. The loss per share stood at $2.91, exceeding the analyst projection of $2.73 per share. More concerning for investors was the company’s forecast for 2025 sales, estimated between $1.5 billion and $2.5 billion—significantly below the $3.26 billion consensus estimate.
CEO Stéphane Bancel reaffirmed Moderna’s focus on cutting costs and streamlining its research and development (R&D) efforts. The company plans to reduce R&D expenses by up to $1.1 billion by 2027, primarily by halting early-stage projects and prioritizing late-stage drug approvals. Moderna has already trimmed $1 billion in costs, positioning itself for leaner operations in the coming years.
Technical Analysis: Key Levels to Watch
From a technical perspective, NASDAQ:MRNA shares closed Friday’s session down 0.38%, showing hesitation despite the broader market’s strength. The stock is currently hovering near a critical support zone—the one-month low. Should this level fail to hold, a further decline towards the $25 region could be the next stop.
On the upside, a breakout above the 38.2% Fibonacci retracement level could alter the trajectory for Moderna’s stock, potentially signaling a bullish reversal. However, with the Relative Strength Index (RSI) at 41.46, the stock remains in weak momentum territory, suggesting that bullish conviction is still lacking.
Outlook: Can Moderna Reignite Investor Confidence?
Moderna’s near-term outlook remains uncertain, as the company grapples with declining COVID vaccine sales, weaker-than-expected 2025 revenue projections, and an ongoing shift in its R&D strategy. However, its pipeline of combination vaccines and upcoming approvals may offer a longer-term upside if execution is successful.
Technically, NASDAQ:MRNA needs to hold its key support zone and break above the 38.2% Fibonacci retracement to shift market sentiment positively. Until then, investors should watch for further signals of strength, particularly in trading volume and RSI movement, before confirming a potential bullish turnaround.
In the coming months, all eyes will be on Moderna’s next earnings report and the market’s reaction to its cost-cutting measures and pipeline advancements. The stock’s ability to sustain recent gains—or break lower—will depend on whether the company can deliver on its strategic shifts and stabilize its revenue trajectory.
MRNA Moderna Options Ahead of EarningsIf you haven`t bought MRNA before the previous earnings:
Now analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 45usd strike price Calls with
an expiration date of 2025-9-19,
for a premium of approximately $3.65.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
The Share Price of Moderna (MRNA) Surged Over 10% in a DayThe Share Price of Moderna (MRNA) Surged Over 10% in a Day
As shown by the chart of pharmaceutical company Moderna (MRNA):
→ 2024 was an extremely difficult year, with the price falling by approximately 60%;
→ however, in early 2025, we can see signs of renewed strength.
During yesterday’s session, Moderna’s (MRNA) share price rose by more than 10%, following news of the first death in the US from H5N1 bird flu. According to Barron’s, Moderna is one of the few pharmaceutical companies currently developing a vaccine for H5N1 bird flu, which is spreading rapidly across North America.
This brings back memories of 2020, when MRNA’s share price surged with a significant bullish gap on news of the COVID-19 vaccine trials.
Interestingly, the 2024 low is near the lower boundary of the 2020 gap, around the $37 level. From a technical analysis perspective, this “gap closure” could be viewed as a bullish sign, supported by yesterday’s price action.
Additionally:
→ there has been a breakout above the descending trend channel that dominated the end of 2024;
→ it is possible that price movements may form a new ascending channel (shown in blue);
→ further growth may be hindered by the psychological resistance level of $50.
According to TipRanks, analysts remain cautious about Moderna’s prospects:
→ only 4 out of 19 analysts recommend buying MRNA shares;
→ the average 12-month price target for MRNA is $62.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Moderna and the HMPV Virus: Your Thoughts?
Hi everyone
What are your views on Moderna following news of the dangerous HMPV virus in China? With Moderna already having a vaccine for HMPV, this could lead to significant orders from various countries.
Could this be a major growth opportunity for the company?
Moderna (MRNA): mRNA Leader Trading at a 90% Discount1️⃣ mRNA Technology Leadership: Moderna is revolutionizing vaccine development with its cutting-edge mRNA platform, positioning itself as a leader in the future of healthcare innovation.
2️⃣ Analyst Targets: With 28 ratings averaging $71.40 and highs of $85, Moderna offers over 60% upside from current levels.
3️⃣ Expanding Pipeline: Moderna’s broadening pipeline includes a variety of treatments, giving it multiple high-growth opportunities in the healthcare sector.
4️⃣ Technical Momentum: Moderna is holding key support at $43.85, with bullish signals of upward movement. The stock is primed for a breakout, supported by increasing volume and positive market sentiment.
📈 Trade Setup:
🎯 Take Profit 1: $50 (+14% potential gain)
🎯 Take Profit 2: $60 (+37% potential gain)
🏆 Take Profit 3: $70 (+59% potential gain)
📉 Stop Loss: $35 ⚠️ (For those with a conservative risk profile, but not necessary for long-term holders like myself)
MRNA Moderna Among My Top 10 Picks for 2025 | Price TargetIf you haven`t bought MRNA on the recent breakout:
My price target for MRNA in 2025 is $55, driven by the following fundamental factors:
Innovative mRNA Technology and Expanding Pipeline:
Moderna has established itself as a leader in mRNA technology, initially gaining prominence through its COVID-19 vaccine. The company is now leveraging this innovative platform to develop a diverse array of therapeutic candidates, with approximately 40 development projects in progress across various fields, including infectious diseases, oncology, and rare genetic disorders. This broad pipeline not only enhances Moderna's potential for future revenue but also positions it to capitalize on emerging healthcare needs as the demand for advanced therapies continues to rise.
Projected Revenue Growth:
Despite facing financial challenges, including recent losses, Moderna's revenue outlook remains promising. The company is forecasting sales between $2.5 billion and $3.5 billion for 2025, which analysts believe could be conservative given the anticipated rollout of new vaccines and treatments. If successful, these products could significantly boost sales and profitability, driving investor confidence and stock price appreciation 16. Market projections suggest that if Moderna successfully navigates its clinical trials and product launches, the stock could reach around $80 per share by 2025.
Strategic Partnerships and Collaborations:
Moderna's strategic collaborations with major pharmaceutical companies enhance its development capabilities and market access. These partnerships are crucial for accelerating product development and increasing the adoption of its mRNA technology across various therapeutic areas. By aligning with established players in the industry, Moderna can leverage additional resources and expertise to bring its innovations to market more effectively.
Market Sentiment and Recovery Potential:
Currently trading at lower valuations due to past performance fluctuations, Moderna's stock is positioned for recovery as investor sentiment shifts with positive developments in its pipeline. The company's five-year growth trajectory shows resilience despite recent setbacks, indicating potential for a rebound as new products come to market. Analysts remain optimistic about Moderna's long-term prospects, suggesting that as the market recognizes the value of its innovative therapies, the stock could see substantial gains.
$MRNA hasn't been here since APRIL 2020.. pt. 2Posted a quick chart via phone earlier but had to take a look on the desktop. A crucial point here at a supply that once took off 4 years ago.. interesting. Target is $35, leave runners once $36 hits. This could have been a bottom for NASDAQ:MRNA but after the rebalancing of the NASDAQ this may bottom out at $30.
WSL
Moderna (MRNA) Stock Plummets on Weak Sales OutlookModerna Inc. (NASDAQ: NASDAQ:MRNA ) is facing tough times as its stock dropped over 11% during Thursday’s premarket trading session. The biotech giant, known for its breakthrough COVID-19 vaccine, released a disappointing sales outlook for the upcoming years, sparking a significant sell-off among investors.
Weak Sales Outlook and Pipeline Adjustments
Moderna (NASDAQ: NASDAQ:MRNA ) has projected sales between $2.5 billion and $3.5 billion for 2025, a far cry from the multi-billion dollar revenues seen during the peak of the COVID-19 pandemic. This forecast falls below analysts’ expectations, who anticipated revenues of $3.27 billion for 2024 and $3.74 billion for 2025.
The company’s revenue has been declining since the pandemic boom, with 2023 expected to be the lowest annual revenue since its first COVID-19 vaccine launch in late 2020. Moderna (NASDAQ: NASDAQ:MRNA ) is now betting on its 10 new product launches by 2027 to drive an average annual growth rate of 25% in revenue between 2026 and 2028. However, Moderna CFO James Mock highlighted the uncertainty of the COVID-19 and RSV markets, admitting that these new products may not contribute significant revenue until later years.
Moderna’s strategic pivot includes significant cost-cutting measures, with plans to slash $1.1 billion in expenses by 2027. This includes reducing R&D spending from an expected $4.8 billion this year to between $3.6 billion and $3.8 billion by 2027. Despite these reductions, the company is still committed to advancing its pipeline, which includes new mRNA vaccines against RSV, norovirus, and cancer, among others.
Challenges Ahead: Competition and Pipeline Delays
Moderna’s market position is increasingly challenged by competitors like Pfizer (PFE) and GSK (GSK), who are also pursuing expanded approvals for their RSV vaccines in the same high-risk adult age groups. Moderna’s recent decision to drop its request for fast-track approval of its standalone flu vaccine reflects its strategic realignment towards combination shots that offer protection against multiple viruses, including COVID-19 and influenza.
The company's standalone flu shot, mRNA-1010, recently met immune-response targets in clinical trials, but it's still a long way from regulatory approval. Moderna's CEO, Stéphane Bancel, remains optimistic about the company's robust drug development capabilities, boasting that Moderna's rate of success from phase one to phase three trials is “six times higher” than the industry average.
Technical Outlook
Technically, Moderna's stock price is reflecting the weak fundamentals. The stock is down 10.45% in premarket trading, which adds to the already bearish momentum. On Wednesday, the Relative Strength Index (RSI) for Moderna (NASDAQ: NASDAQ:MRNA ) was 37, indicating a weakened position. The current dip below the $73 mark will likely push the RSI further into oversold territory, raising concerns about heightened selling pressure.
The critical technical level to watch is the $60 pivot, a major support zone that aligns with the September 2020 lows. Should Moderna’s stock breach this support, it could trigger a cascade of selling as investors lose confidence, potentially leading to a more severe downturn. This level has historically served as a strong base, and a breakdown could erase gains made over the last four years.
What’s Next for Moderna?
While Moderna’s long-term prospects hinge on the successful launch of its new mRNA-based therapies, the immediate outlook appears bleak. The company’s efforts to expand into new markets like RSV and flu vaccines are promising, but the revenue impact of these products won’t be felt until at least 2025. Investors should brace for volatility as the company navigates through a post-pandemic market landscape with reduced COVID-19 vaccine sales and increasing competition.
For now, Moderna's technical indicators signal caution. The stock's proximity to major support zones and the bearish momentum could prompt further declines if market sentiment does not improve. Investors are advised to keep a close eye on how the company’s strategic decisions unfold and whether Moderna (NASDAQ: NASDAQ:MRNA ) can successfully deliver on its ambitious pipeline goals in the face of growing market challenges.
MRNA, bound for exponential growth! MASSIVE RISE in 12 months!MRNA went parabolic during the COVID era reaching as high as 500. Then it went on a cooling down mode coincindingly when the pandemic has started fading.
Now a BIG SHIFT has been registered based on its long term data metrics. This is massive because it took the stock 2.5 years to make this happen again.
A breakout has been spotted on its long term trend. We got a break in structure confirming that major position takers has started piling up already for that new round of massive growth prospect.
Histogram registered it's elusive 'hop' over the line already. First time in ages. The most awaited confirmation is ON.
Best seeding season is NOW.
This will be an investors' gem.
Spotted at 140.0
Interim target at 300.0
Long term: 500.
TAYOR.






















